$KN

Knowles Corp (KN): Results of Operations and Financial Condition

Knowles Corp (KN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026.htm EX-99.1 Document Exhibit 99.1 Financial Contact: Sarah Cook Knowles Investor Relations Email: investorrelations@knowles.com Knowles Reports Q2 2026 Financial Results and Provides Outlook for Q3 2026 Q2 Revenues Increased 14% on a Year over Year Basi

Original reporting
Published Jul 23, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 23, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$KN
Bullish
medium confidence
Mentioned
$KN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$KNBullishMed
01

Why it matters

The key tradable elements are the Q2 print (revenues, GAAP and non-GAAP EPS, operating cash flow) and the explicit Q3 guidance ranges, plus management’s 2026 growth expectations (10-12% revenue growth and adjusted EBITDA growth >20%).

02

Market read

This filing updates the company’s near-term earnings expectations via Q3 guidance and reinforces a 2026 growth framework tied to bookings and backlog.

03

What to watch

Cash from operations was $28.2 million in Q2 versus $36.4 million in Q2 2025, so traders may scrutinize working-capital swings and the sustainability of operating cash conversion into future quarters.

Relevance 7/10Novelty 8/10Timing: after-hours, ahead of Q3 2026 results

Background

Knowles filed an SEC 8-K (Item 2.02) with Q2 2026 results for continuing operations and provided forward guidance for the quarter ending September 30, 2026.

Company-level read

Ticker impact

$KNBullishMedium confidence
Context

Knowles reported Q2 2026 results and issued Q3 2026 guidance for revenues $167 to $177 million and EPS $0.34 to $0.38 (non-GAAP).

Expected impact

Likely near-term positive bias if investors view the Q3 range and 2026 outlook as credible versus expectations, with upside/downside sensitivity to revenue and non-GAAP EPS midpoint.

Evidence & confidence

This is a primary 8-K earnings release with explicit Q3 guidance ranges and a stated 2026 revenue growth target (10-12%) and adjusted EBITDA growth (>20%).

Market effects

Signals demand and margin durability in specialty electronic components (precision devices, medtech, defense, industrial, electrification) that can influence sentiment across the component supply chain.

Limited, primarily company-specific given the filing is not a macro or regional policy event.

Moderate, as defense and medtech end markets can affect broader electronics component demand expectations, but the disclosure is company-specific.

Counterpoint

The outlook is growth-oriented, but investors may focus on whether bookings/backlog translate into revenue timing, and whether non-GAAP strength masks GAAP or cash flow volatility.

Key entities

  • Knowles Corp

    Specialty electronic components manufacturer reporting Q2 2026 results and issuing Q3 2026 guidance.

  • Jeffrey Niew

    President and CEO quoted on performance, bookings/backlog, and 2026/2027 outlook.

Related articles

$KNMed

Knowles Targets 30% Margins as Specialty Components Drive Growth

Knowles Corporation (KN) aims for 30% EBITDA margins within 36 months, driven by growth in specialty components. The company reported 11% EBITDA growth from 2017-2025, with recent organic growth exceeding 10%. Precision Devices is expected to grow over 15% this year, while hearing-health margins remain above 50% gross and 40% EBITDA. Knowles plans to reduce debt and continue selective acquisitions.

$UNFIMedAI 8/10

United Natural Foods (UNFI) Calls the Bottom and Guides for Growth Again

United Natural Foods (UNFI) reported Q4 adjusted EPS of $0.69, beating estimates, but revenue of $7.64B missed expectations. The company guided fiscal 2027 sales to $31.2B-$31.8B, up from $31.15B in 2026. Adjusted EBITDA rose 27% to $701M, and free cash flow hit a record $323M. Management expects fiscal 2027 adjusted EPS of $3.00-$3.50. Hedge fund interest declined in Q2.

MedAI 8/10

LuxExperience B.V. Q4 2026 Earnings Call Summary

LuxExperience B.V. reported Q4 2026 earnings, highlighting EBITDA break-even 15 months post-acquisition. Mytheresa reached EUR 1 billion in sales, while NET-A-PORTER and MR PORTER returned to growth. YOOX cut losses by half. Management expects 2%-3% EBITDA margins in FY 2027 and EUR 4 billion in net sales by 2028. The company improved operational efficiency and strengthened its financial position.